Inicio temprano de terapia a base de insulina, pacientes con Diabetes

Por la Dra. Rutila Castañeda Limones. Especialista en Endocrinología Clínica Eugenio Sue. Cédula: 1237319

Referencias:

1. Kahn SE, et al. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46(1):3–19. 
2. Inzucchi SE, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96. 
3. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461–98. 
4. Summary of Revisions: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019 Jan; 42(Supplement 1): S4-S6.
5. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019; 42 (Suppl.1, s90-s102). 
6. Tibaldi J, et al. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract 2007;61:633–44.
7. Choe C, et al. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 2007;99:357–67.
8. Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2013;32:193-203
9. Rodbard HW, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med 2013;30:1298–304.
10. Onishi Y, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013;4(6):605-12.
11. Gough SCL, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42.
12. Meneghini L, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858–64.
13. Hollander P, et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab 2014;17:202–6.
14. Wysham C, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017;318(1):45–56.
15. Marso SP, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017;377(8):723–32.

Material desarrollado con fines de educación médica continua.

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Código interno de aprobación: MX21XUM00004.